Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pLADD
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
pLADD (personalized Live Attenuated Double-Deleted *Listeria monocytogenes*) is an individualized, neoantigen-based immunotherapy developed by Aduro Biotech for the treatment of microsatellite stable (MSS) metastatic colorectal cancer. Utilizing Aduro's proprietary LADD platform, the therapy consists of attenuated *Listeria monocytogenes* strains engineered to express multiple patient-specific tumor neoantigens identified through genomic sequencing of the patient's tumor. Upon intravenous administration, the *Listeria* vector is taken up by dendritic cells, where it triggers both innate and adaptive immune responses, specifically activating CD8+ T cells against the tumor-specific mutations. Although it reached Phase 1 clinical testing, the program was deprioritized by Aduro in 2019 during a strategic pipeline refocusing.
- Other names
- personalized Live Attenuated Double-Deleted Listeria monocytogenes
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on pLADD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pLADD.